Onyx Biotec Ltd. Stock Analysis ONYX.NS

Onyx Biotec Ltd. Is a pharmaceutical company, which engages in the manufacture and sale distribution of generic and proprietary pharmaceutical products. The company is headquartered in Chandigarh, Chandigarh and currently employs 357 full-time employees. The company went IPO on 2024-11-22. The company develops, manufactures and distributes generic and branded pharmaceutical products in various forms, like water for injection (WFI), dry powder injections, and dry powder syrup. WFI is a sterile preparation of water, which is supplied only in single-dose containers, indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection. Its dry powder injections include Ceftriaxone and Sulbactam for Injection, Cefazoline Sodium for Injection, and Cefepime and Tazobactam for Injection, among others. Its dry powder syrups include Cefpodoxime Proxetil, Cefuroxime Axetil, and others. Its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Its services also include preparation and filing of regulatory dossiers in the Indian and global markets.